Health

STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 20:36:25 UTC.

Briefings

Artiva Biotherapeutics announced the shutdown of its Phase 2 cell therapy trial following two patient deaths. One death resulted from a neurological complication linked to prior chemotherapy, while the second death occurred two months post-treatment with an unresolved cause. The company, based in San Diego, stated these events are part of a broader series of safety issues in the field. The trial is winding down as researchers continue to investigate the causes of these adverse events.

Key points

• Artiva Biotherapeutics announced the shutdown of its Phase 2 cell therapy trial following two patient deaths.
• One death resulted from a neurological complication linked to prior chemotherapy, while the second death occurred two months post-treatment with an unresolved cause.

Context

This finding is significant as it marks a halt in a promising research field for autoimmune diseases, following a series of safety events that have emerged in the industry. The company, based in San Diego, stated these events are part of a broader series of safety issues in the field.

Limitations

The evidence is limited to the company's statement regarding the two deaths and the reasons provided. The specific causes of the neurological complication and the unresolved cause of the second death are not fully determined. The timeline of the trial and the full scope of safety events are not detailed in the provided text.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/10/2026, 22:22:23 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifihpxtkysonxtop22mn4dcia2kthyz3jdvwdxmhsxxylmx6gzboi